<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>

<!-- This file generated using Python HTMLgen module. -->
<HEAD>
  <META NAME="GENERATOR" CONTENT="HTMLgen 2.2.2">
        <TITLE>Drug Interaction Knowledge Base 1.2</TITLE>

 <LINK rel=stylesheet href="html/HTMLgen.css" type="text/css" title="html/HTMLgen.css">
</HEAD>
<BODY BGCOLOR="#FFFFFF" TEXT="#000000" LINK="#0000FF" VLINK="#EE0000">
<span style="width: 60px"></span> 
<IMG src="./images/blank.gif" height="22" width="66" alt="blank.gif"> 
<IMG src="./images/blank.gif" height="22" width="66" alt="blank.gif"> 
<IMG src="./images/blank.gif" height="22" width="66" alt="blank.gif"> 
<H3>Drug Interaction Knowledge Base 1.2</H3>
<H2>bupropion_does_not_inhibit_cyp2d6</H2>
<HR>

<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>

<!-- This file generated using Python HTMLgen module. -->
<HEAD>
  <META NAME="GENERATOR" CONTENT="HTMLgen 2.2.2">
        <TITLE></TITLE>

 <LINK rel=stylesheet href="html/HTMLgen.css" type="text/css" title="html/HTMLgen.css">
</HEAD>
<BODY BGCOLOR="#FFFFFF" TEXT="#000000" LINK="#0000FF" VLINK="#EE0000">
<b>You can go to DIKB assertion index here:</b>  
<A HREF="/dikb-evidence/index.html">DIKB assertion index</A>
<br><b>You can go to DIKB the home page here:</b>  
<A HREF="/dikb-evidence/front-page.html">DIKB Front Page</A>

<P>

<a name="
bupropion_does_not_inhibit_cyp2d6
"></a>
<b>Assertion:
bupropion does_not_inhibit cyp2d6
</b>
<BR>
<A NAME="Evidence"></A>
<P><TABLE border=2 cellpadding=4 cellspacing=1 width="100%">
<CAPTION align=top><STRONG>Evidence</STRONG></CAPTION>
<TR><TD Align=left >No evidence for!</TD>
</TR>
<TR><TD Align=left ><STRONG>Evidence Against (item 0)</STRONG></TD>
<TD Align=left ><STRONG>Evidence Type: </STRONG>Non_traceable_Drug_Label_Statement</TD>
<TD Align=left ><STRONG>Pointer: </STRONG>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/resource/structuredProductLabelMetadata/c2126e2d-3b46-</TD>
<TD Align=left ><STRONG>Reviewer: </STRONG>boycer</TD>
</TR>
<TR><TD Align=left ></TD>
<TD Align=left ><STRONG>Quote: </STRONG>Drugs Metabolized by Cytochrome P450IID6 (CYP2D6): Many drugs, including most antidepressants (SSRIs, many tricyclics), beta-blockers, antiarrhythmics, and antipsychotics are metabolized by the CYP2D6 isoenzyme. Although bupropion is not metabolized by this isoenzyme, bupropion and hydroxybupropion are inhibitors of the CYP2D6 isoenzyme in vitro. In a study of 15 male subjects (ages 19 to 35 years) who were extensive metabolizers of the CYP2D6 isoenzyme, daily doses of bupropion given as 150mg twice daily followed by a single dose of 50mg desipramine increased the Cmax, AUC, and t1/2 of desipramine by an average of approximately 2-, 5- and 2-fold, respectively. The effect was present for at least 7 days after the last dose of bupropion. Concomitant use of bupropion with other drugs metabolized by CYP2D6 has not been formally studied.</TD>
</TR>
<TR><TD Align=left ></TD>
<TD Align=left ><STRONG>Assumptions: </STRONG></TD>
</TR>
<TR><TD Align=left ><STRONG>Evidence Against (item 1)</STRONG></TD>
<TD Align=left ><STRONG>Evidence Type: </STRONG>EV_PK_DDI_NR</TD>
<TD Align=left ><STRONG>Pointer: </STRONG>http://www.ncbi.nlm.nih.gov/pubmed/15876900</TD>
<TD Align=left ><STRONG>Reviewer: </STRONG>boycer</TD>
</TR>
<TR><TD Align=left ></TD>
<TD Align=left ><STRONG>Quote: </STRONG><br><br>route of administration: oral<br><br>study duration: &quot;dextromethorphan (30-mg oral dose) was administered to smokers at baseline and after 17 days of treatment with either bupropion sustained-release (150 mg twice daily) or matching placebo. Subjects quit smoking 3 days before the second dextromethorphan administration.&quot;<br><br>population: 21 smoking, 9 female, 11 male<br><br>tested for known CYP450 polymorphisms? yes ... all participants were considered CYP2D6 extensive metabolizers according to dextromethorphan:dextrorphan metabolite ratio<br><br>ages: 21 - 40<br><br>NOTE: &quot;24-hour period preceding each laboratory visit. Two subjects reported taking medications that could potentially affect CYP2D6 metabolism and therefore alter bupropion concentrations (one reported use of hormone replacement therapy and another oral contraceptives).&quot;<br><br>description:<br>&quot;Among those taking bupropion, DM/DX ratio in-<br>creased significantly at the second assessment relative to the first (0.012 ? 0.012 vs. 0.418 ? 0.302; P &lt; 0.0004) (Fig. 1). No such change was observed in those randomized to placebo (0.009 ? 0.010 vs. 0.017 ? 0.015; P = NS). Of those receiving bupropion, 46% (6/13) were phenotypically poor metabolizers after treatment.&quot;<br><br><br></TD>
</TR>
<TR><TD Align=left ></TD>
<TD Align=left ><STRONG>Assumptions: </STRONG></TD>
</TR>
</TABLE><P>

<BR>

</BODY> </HTML>

<b>You can go to DIKB assertion index here:</b>  
<A HREF="/dikb-evidence/index.html">DIKB assertion index</A>
<br><b>You can go to DIKB the home page here:</b>  
<A HREF="/dikb-evidence/front-page.html">DIKB Front Page</A>

<P>

<BR><BR><a rel="license" href="http://creativecommons.org/licenses/by-nc-sa/3.0/"><img alt="Creative Commons License" style="border-width:0" src="http://i.creativecommons.org/l/by-nc-sa/3.0/88x31.png" /></a><br /><span xmlns:dct="http://purl.org/dc/terms/" href="http://purl.org/dc/dcmitype/Dataset" property="dct:title" rel="dct:type">Drug Interaction Knowledge Base (DIKB)</span> by <a xmlns:cc="http://creativecommons.org/ns#" href="http://www.dbmi.pitt.edu/person/richard-boyce-phd" property="cc:attributionName" rel="cc:attributionURL">Richard D. Boyce</a> is licensed under a <a rel="license" href="http://creativecommons.org/licenses/by-nc-sa/3.0/">Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License</a>.

<P><HR>
<span style="width: 60px"></span> 
<IMG src="./images/blank.gif" height="22" width="66" alt="blank.gif"> 
<IMG src="./images/blank.gif" height="22" width="66" alt="blank.gif"> 
<IMG src="./images/blank.gif" height="22" width="66" alt="blank.gif"> 
<BR><IMG src="./images/logo.jpg" alt="logo.jpg" align="bottom">
<FONT SIZE="-1"><P>Copyright &#169 (c) 2005-2012 Richard David Boyce<BR>All Rights Reserved<BR>

Comments to author: <A HREF="mailto:&#114;d&#98;2&#48; &#97;t&#32;p&#105;t&#116; &#60;d&#111;t&#62; &#101;d&#117;">rdb20 at pitt <dot> edu</A><br>
Generated: Thu Jul 30, 2015 <BR><hr>
</FONT>
</BODY> </HTML>
